← Back to Search

Treatment for Non-Small Cell Lung Cancer (INSIGHT Trial)

N/A
Waitlist Available
Led By Steve Springmeyer, MD
Research Sponsored by Biodesix, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Summary

The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Physician Treatment Patterns Description
Secondary study objectives
Immunotherapy Stratification by Overall Survival
Immunotherapy Stratification by Progression-Free Survival
Immunotherapy outcomes in VeriStrat Poor vs. Good subjects.
+4 more
Other study objectives
Changes in GeneStrat
Correlation between the VeriStrat test and Immunotherapy tests.
Determination of Immunotherapy tests ability to stratify subjects based on treatment.
+2 more

Find a Location

Who is running the clinical trial?

Biodesix, Inc.Lead Sponsor
7 Previous Clinical Trials
2,991 Total Patients Enrolled
Steve Springmeyer, MDPrincipal InvestigatorBiodesix, Inc.
Linda Traylor, Ph.DPrincipal InvestigatorBiodesix, Inc.
~609 spots leftby Dec 2025